Posted by Michael Wonder on 17 Oct 2016
Emtricitabine/rilpivirine/tenofovir alafenamide in HIV: added benefit not proven
17 October 2016 - Research questions on adolescents not investigated/evidence on components not simply transferable to the combination.
The drug combination emtricitabine with rilpivirine and tenofovir alafenamide fumarate (Odefsey) is approved for the treatment of adults and adolescents infected with human immunodeficiency virus type 1. In an early benefit assessment, the German IQWiG has now examined whether in these patients this combination offers advantages over the appropriate comparator therapies.
According to the findings, such an added benefit is not proven: no informative data were available for any of the four research questions. IQWiG did not accept the drug manufacturer’s postulate that the evidence on the individual drugs was transferable to the combination. It also did not accept the assumption that the same comparator therapies were appropriate for adolescents as for adults.
